Security key
221015100
Corvus Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (CRVS)
CUSIP: 221015100
Q3 2020 13F Holders as of 30 Sep 2020
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Total 13F shares
- 17,216,699
- Total 13F value
- $69,036,016
- Share change
- -3,225,708
- Put/Call ratio
- 1.5%
- SEC-reported price per share
- $4.01
- Number of holders
- 33
- Value change
- -$11,684,715
- Number of buys
- 13
- Number of sells
- 19
- Shares outstanding
- 91,091,040
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q3 2020
Institutions
33
Top holders
10
CRVS full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q4 2020
Previous quarter: Q2 2020
Corvus Pharmaceuticals, Inc. SEC filings
Corvus Pharmaceuticals, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 221015100
Recent filing periods:
Ownership snapshot
Top reported holders of CRVS - Corvus Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
ORBIMED ADVISORS LLC
Disclosed value leader
ORBIMED ADVISORS LLC
Comparable rows
15/15
Latest evidence
30 Jun 2020
13F
Lead comparable stake: 7.4%
Showing 1-6 of 15 holder rows.
Quick read
ORBIMED ADVISORS LLC leads the comparable SEC ownership view at 7.4%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens ORBIMED ADVISORS LLC's linked filing trail.
Comparable ownership
Top 5
ORBIMED ADVISORS LLC
7.4%
ADAMS STREET PARTNERS LLC
3.6%
Novo Holdings A/S
3.2%
BVF INC/IL
1.9%
MILLENNIUM MANAGEMENT LLC
1.3%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC |
13F
Company
|
7.4%
|
$18,408,000
6,767,584 shares
|
— | 30 Jun 2020 |
| ADAMS STREET PARTNERS LLC |
13F
Company
|
3.6%
|
$8,910,000
3,275,616 shares
|
— | 30 Jun 2020 |
| Novo Holdings A/S |
13F
Company
|
3.2%
|
$7,963,000
2,927,560 shares
|
— | 30 Jun 2020 |
| BVF INC/IL |
13F
Company
|
1.9%
|
$4,739,000
1,742,112 shares
|
— | 30 Jun 2020 |
| MILLENNIUM MANAGEMENT LLC |
13F
Company
|
1.3%
|
$3,244,000
1,192,742 shares
|
— | 30 Jun 2020 |
| RENAISSANCE TECHNOLOGIES LLC |
13F
Company
|
1.1%
|
$2,807,000
1,031,900 shares
|
— | 30 Jun 2020 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2020
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
33
Shares
17,216,699
Rows available
33
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2020 vs Q2 2020 Across Filers
Q2 2020 holders
34
Q3 2020 holders
33
Holder diff
-1
| Investor | Q2 2020 Shares | Q3 2020 Shares | Share Diff | Share Chg % | Q2 2020 value | Q3 2020 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend